Experts: Tread Carefully In New, More Ambiguous Patent Environment
This article was originally published in The Gray Sheet
Executive Summary
Device companies seeking to obtain a patent must act conservatively in the wake of an uncertain legal environment created by recent Supreme Court patent decisions.
You may also be interested in...
Supreme Court Gives Some Relief, But Leaves Open Questions For Dx Patents
Diagnostics and biotech firms praised a June 28 Supreme Court opinion for allowing judges some flexibility in ruling on the patent-eligibility of "process" claims, but patent attorneys warn that many issues remain unsettled
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.